These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 26259990)

  • 1. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series.
    Shi VY; Tran K; Patel F; Leventhal J; Konia T; Fung MA; Wilken R; Garcia MS; Fitzmaurice SD; Joo J; Monjazeb AM; Burrall BA; King B; Martinez S; Christensen SD; Maverakis E
    J Am Acad Dermatol; 2015 Oct; 73(4):645-54. PubMed ID: 26259990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream.
    Garcia MS; Ono Y; Martinez SR; Chen SL; Goodarzi H; Phan T; Wehrli LN; Miyamura Y; Fung MA; Maverakis E
    Melanoma Res; 2011 Jun; 21(3):235-43. PubMed ID: 21464773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.
    Green DS; Bodman-Smith MD; Dalgleish AG; Fischer MD
    Br J Dermatol; 2007 Feb; 156(2):337-45. PubMed ID: 17223875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma.
    Bong AB; Bonnekoh B; Franke I; Schön M; Ulrich J; Gollnick H
    Dermatology; 2002; 205(2):135-8. PubMed ID: 12218228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Imiquimod, pegylated interferon-alpha-2b and interleukin-2 in the treatment of cutaneous melanoma metastases].
    Loquai C; Nashan D; Metze D; Beiteke U; Rüping KW; Luger TA; Grabbe S
    Hautarzt; 2004 Feb; 55(2):176-81. PubMed ID: 14968329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma.
    Green DS; Dalgleish AG; Belonwu N; Fischer MD; Bodman-Smith MD
    Br J Dermatol; 2008 Sep; 159(3):606-14. PubMed ID: 18616776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T Cells Dominate the Local Immune Response Induced by Intralesional IL-2 in Combination with Imiquimod and Retinoid for In-Transit Metastatic Melanoma.
    Ogawa H; Luxardi G; Kirane A; Kulkarni R; Monjazeb AM; Cheng MY; Ma C; Maverakis E
    J Invest Dermatol; 2018 Jun; 138(6):1442-1445. PubMed ID: 29291382
    [No Abstract]   [Full Text] [Related]  

  • 8. Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type.
    Swetter SM; Chen FW; Kim DD; Egbert BM
    J Am Acad Dermatol; 2015 Jun; 72(6):1047-53. PubMed ID: 25791801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detailed protocol for administration of intralesional IL-2 for the treatment of Stage IIIc and IV M1a metastatic melanoma based on current NCCN guidelines.
    Patel F; Wilken R; Burrall B; Martinez S; Wells V; King B; Maverakis E
    Dermatol Online J; 2014 Nov; 20(11):. PubMed ID: 25419744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regression of internal melanoma metastases following application of topical imiquimod to overlying skin.
    Miller AK; Dusing R; Meggison A; Aires D
    J Drugs Dermatol; 2011 Mar; 10(3):302-5. PubMed ID: 21369648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2].
    Dehesa LA; Vilar-Alejo J; Valerón-Almazán P; Carretero G
    Actas Dermosifiliogr; 2009 Sep; 100(7):571-85. PubMed ID: 19715642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma in situ treated successfully using imiquimod after nonclearance with surgery: review of the literature.
    Ellis LZ; Cohen JL; High W; Stewart L
    Dermatol Surg; 2012 Jun; 38(6):937-46. PubMed ID: 22338583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using topical imiquimod for the management of positive in situ margins after melanoma resection.
    Pandit AS; Geiger EJ; Ariyan S; Narayan D; Choi JN
    Cancer Med; 2015 Apr; 4(4):507-12. PubMed ID: 25620351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of locally metastatic melanoma: a novel approach.
    Shistik G; Prakash AV; Fenske NA; Glass LF
    J Drugs Dermatol; 2007 Aug; 6(8):830-2. PubMed ID: 17763615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic melanoma - a review of current and future treatment options.
    Maverakis E; Cornelius LA; Bowen GM; Phan T; Patel FB; Fitzmaurice S; He Y; Burrall B; Duong C; Kloxin AM; Sultani H; Wilken R; Martinez SR; Patel F
    Acta Derm Venereol; 2015 May; 95(5):516-24. PubMed ID: 25520039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Outcomes of Melanoma In Situ Treated With Topical 5% Imiquimod Cream: A Retrospective Review.
    Park AJ; Paul J; Chapman MS; Samie FH
    Dermatol Surg; 2017 Aug; 43(8):1017-1022. PubMed ID: 28328708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local cryosurgery and imiquimod: A successful combination for the treatment of locoregional cutaneous metastasis of melanoma: A case series.
    Rivas-Tolosa N; Ortiz-Brugués A; Toledo-Pastrana T; Baradad M; Traves V; Soriano V; Sanmartín V; Requena C; Martí R; Nagore E
    J Dermatol; 2016 May; 43(5):553-6. PubMed ID: 26660713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In-transit metastasis in melanoma: Efficacy of topical imiquimod combined with carbon dioxide laser or with electrocautery].
    Elfatoiki FZ; Longvert C; Clerici T; Bourgault-Villada I; Roudier-Pujol C; Vasseur E; Saiag P
    Ann Dermatol Venereol; 2014 Feb; 141(2):106-10. PubMed ID: 24507204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Complete remission of cutaneous satellite and in-transit metastases. After intralesional therapy with interleukin-2 in 2 patients with malignant melanoma].
    Pföhler C; Steinhäuser S; Wagner A; Ugurel S; Tilgen W
    Hautarzt; 2004 Feb; 55(2):171-5. PubMed ID: 14968328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases.
    Radny P; Caroli UM; Bauer J; Paul T; Schlegel C; Eigentler TK; Weide B; Schwarz M; Garbe C
    Br J Cancer; 2003 Nov; 89(9):1620-6. PubMed ID: 14583759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.